Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin

Dipeptidyl Peptidase ◽

Efficacy And Safety ◽

Dipeptidyl Peptidase 4 ◽

Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus; the repaglinide glucose oscillation study in Fukuoka (REGO-F)

Diabetology International ◽

10.1007/s13340-020-00426-w ◽

2020 ◽

Vol 11 (3) ◽

pp. 274-282

Author(s):

Yuichi Terawaki ◽

◽

Chikayo Iwaya ◽

Takashi Nomiyama ◽

Dai Shimono ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Japanese Patients ◽

Dipeptidyl Peptidase ◽

Efficacy And Safety ◽

Dipeptidyl Peptidase 4 ◽

Insulin Secretagogue ◽

Efficacy and safety of novel dipeptidyl-peptidase-4 inhibitor evogliptin in the management of type 2 diabetes mellitus: A meta-analysis

Indian Journal of Endocrinology and Metabolism ◽

10.4103/ijem.ijem_418_20 ◽

2020 ◽

Vol 24 (5) ◽

pp. 434

Author(s):

Deep Dutta ◽

Saptarshi Bhattacharya ◽

Aishwarya Krishnamurthy ◽

LokeshKumar Sharma ◽

Meha Sharma

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Meta Analysis ◽

Dipeptidyl Peptidase ◽

Efficacy And Safety ◽

Dipeptidyl Peptidase 4 ◽

Study of Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin in Patients with Type 2 Diabetes Mellitus

Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) ◽

10.5649/jjphcs.39.309 ◽

2013 ◽

Vol 39 (5) ◽

pp. 309-321

Author(s):

Toshiyuki Kokuryo ◽

Kenichiro Hayashi ◽

Masayuki Yamakawa

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Efficacy And Safety ◽

Dipeptidyl Peptidase 4 ◽

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus

Diabetologia ◽

10.1007/s00125-006-0416-z ◽

2006 ◽

Vol 49 (11) ◽

pp. 2564-2571 ◽

Cited By ~ 412

Author(s):

I. Raz ◽

M. Hanefeld ◽

L. Xu ◽

C. Caria ◽

D. Williams-Herman ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Efficacy And Safety ◽

Dipeptidyl Peptidase 4 ◽

The dipeptidyl peptidase-4 inhibitor vildagliptin does not affect ex vivo cytokine response and lymphocyte function in patients with type 2 diabetes mellitus

Diabetes Research and Clinical Practice ◽

10.1016/j.diabres.2013.12.039 ◽

2014 ◽

Vol 103 (3) ◽

pp. 395-401 ◽

Cited By ~ 12

Author(s):

P.C.M. van Poppel ◽

M.S. Gresnigt ◽

P. Smits ◽

M.G. Netea ◽

C.J. Tack

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Ex Vivo ◽

Dipeptidyl Peptidase ◽

Cytokine Response ◽

Lymphocyte Function ◽

Dipeptidyl Peptidase 4 ◽

First-in-Human, Single-Ascending Dose and Food Effect Studies to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cetagliptin, a Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus

Clinical Drug Investigation ◽

10.1007/s40261-021-01088-5 ◽

2021 ◽

Author(s):

Lu Wang ◽

Jinmiao Lu ◽

Sufeng Zhou ◽

Yuqing Zhao ◽

Lijun Xie ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Food Effect ◽

Dipeptidyl Peptidase ◽

Pharmacokinetics And Pharmacodynamics ◽

Dipeptidyl Peptidase 4 ◽

Effects of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin on Blood Pressure in Hypertensive Patients with Type 2 Diabetes Mellitus

American Journal of Hypertension ◽

10.1093/ajh/hpz065 ◽

2019 ◽

Vol 32 (7) ◽

pp. 695-702 ◽

Cited By ~ 9

Author(s):

Shinji Kishimoto ◽

Yoshihiko Kinoshita ◽

Takeshi Matsumoto ◽

Tatsuya Maruhashi ◽

Masato Kajikawa ◽

...

Keyword(s):

Diabetes Mellitus ◽

Blood Pressure ◽

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Hypertensive Patients ◽

Dipeptidyl Peptidase 4 ◽

Incident cancer risk in dipeptidyl peptidase-4 inhibitor-treated patients with type 2 diabetes mellitus

Cancer Management and Research ◽

10.2147/cmar.s215107 ◽

2019 ◽

Vol Volume 11 ◽

pp. 7427-7438 ◽

Cited By ~ 2

Author(s):

Yeo Jin Choi ◽

Dae Jung Kim ◽

Sooyoung Shin

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Cancer Risk ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Incident Cancer

Risk of Diabetic Retinopathy associated with Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Metformin in Type 2 Diabetes Mellitus

Yakhak Hoeji ◽

10.17480/psk.2020.64.5.402 ◽

2020 ◽

Vol 64 (5) ◽

pp. 402-408

Author(s):

Eunmi Choi ◽

Soo Youn Chung ◽

Bonggi Kim ◽

Jeonghoon Ahn ◽

Soon Young Han

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Diabetic Retinopathy ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase 4 ◽

Clinical overview of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with Type 2 diabetes mellitus

Expert Review of Endocrinology & Metabolism ◽

10.1586/eem.12.69 ◽

2013 ◽

Vol 8 (1) ◽

pp. 21-35 ◽

Cited By ~ 1

Author(s):

Thomas Forst ◽

Andreas Pfützner

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Clinical Overview